Scientific Evidence Demonstrates OPTAVIA®’s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients
Medifast announced that its OPTAVIA metabolic health system is now eligible for reimbursement through Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA), allowing clients to save up to 40% on program costs. This move is significant as over 90% of U.S. adults are metabolically unhealthy, and OPTAVIA's science-backed approach, including Metabolic Synchronization™, aims to reverse metabolic dysfunction by reducing visceral fat and preserving lean muscle mass. Medifast plans to launch new products in 2026 to further support metabolic health, reinforcing its commitment to scientific solutions and comprehensive behavioral support.
Stephens cuts Medifast stock price target to $12 on margin pressures
Stephens has lowered its price target for Medifast (NYSE:MED) stock to $12 from $15, while maintaining an Equal Weight rating, citing margin pressures despite exceeding revenue expectations for Q4 2025. The company faces ongoing challenges from GLP-1 adoption and a value-focused consumer impacting client acquisition. Medifast's future performance hinges on stabilizing coach headcount and successful product refresh initiatives to regain top-line momentum.
Stephens Lowers Medifast (NYSE:MED) Price Target to $12.00
Stephens has decreased its price target for Medifast (NYSE:MED) to $12.00 from $15.00, while maintaining an "equal weight" rating, suggesting a potential 12% upside. This aligns with the consensus analyst rating of "Reduce" and an average price target of $12.00. Medifast recently reported better-than-expected revenue and EPS for the last quarter but remains unprofitable, issuing negative EPS guidance for both the full year 2026 and Q1 2026.
Public company to leave Harbor East headquarters
Medifast, a prominent public company, is relocating its headquarters from Harbor East to Canton this spring. The move means the company will vacate its 51,000 square-foot office space in Harbor East. This follows a period where Medifast's sales plummeted by 60% over three years, prompting a look beyond its traditional weight loss focus.
Medifast Announces Fourth Quarter and Full Year 2025 Financial Results
Medifast announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting a significant decrease in revenue and a net loss for both periods. The company is undergoing a business transformation, shifting its focus towards optimal metabolic health, and provided guidance for the first quarter and full year 2026. Despite financial challenges, Medifast highlighted positive year-over-year coach productivity and an increase in coach-led meetings as signs of future improvement.
Medifast outlines $270M–$300M 2026 revenue target as CEO transition and metabolic health focus drive execution
Medifast (MED) is targeting $270 million to $300 million in revenue by 2026, driven by new product launches and an increased focus on metabolic health. This strategic shift coincides with the upcoming CEO transition to Dan Chard, who previously led the company. The company aims to innovate its product offerings and expand its market reach in the health and wellness sector.
Medifast Q4 Loss Wider Than Expected, Revenues Decline 37% Y/Y
Medifast (MED) reported a wider-than-expected loss of $1.65 per share in Q4 2025, significantly missing the Zacks Consensus Estimate, largely due to a tax provision charge. Revenues declined 36.9% year-over-year to $75.1 million, impacted by a decrease in active earning OPTAVIA coaches and broader weight-loss market pressures, including GLP-1 medications, though revenue did exceed consensus estimates. The company forecasts revenues between $270 million and $300 million for 2026, with an expected loss per share of $1.55 to $2.75.
Medifast, Inc. (NYSE:MED) Q4 2025 Earnings Call Transcript
Medifast (NYSE: MED) reported its Q4 2025 earnings, with an EPS of $-0.55, beating expectations of $-0.76. The company is transitioning from a weight-loss focus to metabolic health, emphasizing its "metabolic synchronization" science to address metabolic dysfunction, catalyzed by GLP-1 drug adoption and CEO Dan Chard's planned departure in June 2026. Despite a revenue decrease of 36.9% year-over-year, Medifast saw improved coach productivity and reinstituted annual guidance for 2026, expecting revenue between $270 million and $300 million and a return to profitability by Q4 2026.
MEDIFAST INC SEC 10-K Report
Medifast, Inc. released its 2025 10-K report, detailing a significant 36% revenue decrease to $385.8 million and a net loss of $(18.7) million, reflecting challenges in its strategic transformation. The company is shifting its focus to holistic metabolic health, with new product innovations planned for 2026, while grappling with a declining coach network and intense competition from weight loss solutions like GLP-1 medications. Medifast aims to enhance digital tools, expand its coach network, and is evaluating potential acquisitions to support future growth.
Medifast (NYSE:MED) Updates Q1 2026 Earnings Guidance
Medifast (NYSE:MED) has updated its Q1 2026 earnings guidance, projecting an EPS of -0.70 to -0.15 against a consensus of -0.26, and revenue guidance of $65.0M–$80.0M compared to a consensus of $78.1M. The company also revised its full-year 2026 EPS guidance to -2.75 to -1.55. MED stock traded around $10.78, with institutional investors holding approximately 95.5% of shares, and analysts maintaining a "Reduce" rating with a $16.50 consensus target.
Earnings call transcript: Medifast Q4 2025 shows significant EPS miss
Medifast Inc. (NYSE:MED) reported a challenging Q4 2025, missing EPS forecasts significantly with -$1.65 against an expected -$0.45, although revenue slightly exceeded expectations at $75.1 million. The company is undergoing a transformation, shifting its focus from traditional weight loss to metabolic health and implementing restructuring efforts, anticipating over $30 million in future savings. Despite a sharp decline in active earning coaches, Medifast highlighted early positive indicators in coach productivity and is reinstituting annual guidance for 2026, projecting revenue between $270-$300 million.
Medifast Inc (NYSE:MED) Reports Mixed Q4 Results with Deepening Losses and Challenging 2026 Outlook
Medifast Inc (NYSE:MED) reported mixed Q4 2025 results, with revenue slightly exceeding expectations but losses deepening significantly. The company's forward guidance for Q1 and full-year 2026 falls well below analyst estimates, largely due to a steep decline in active earning coaches attributed to the rise of GLP-1 medications. Despite a strong balance sheet and a stated strategic pivot towards a metabolic health company, the negative market reaction reflects concerns about sustained revenue decline and stabilization challenges.
Medifast's (NYSE:MED) Q4 CY2025 Sales Top Estimates
Medifast (NYSE:MED) reported Q4 CY2025 results with revenue of $75.1 million, exceeding analyst estimates, despite a 36.9% year-on-year decline. However, the company's GAAP loss of $1.65 per share significantly missed estimates, and its Q1 CY2026 revenue guidance of $72.5 million was below analyst expectations. The company acknowledged a challenging demand environment and is focusing on a new growth and profitability strategy.
Medifast: Q4 Earnings Snapshot
Medifast Inc. (MED) reported a fourth-quarter loss of $18.1 million, or $1.65 per share, with adjusted losses of 55 cents per share. The company posted revenue of $75.1 million for the quarter. For the full year, Medifast reported a loss of $18.7 million on revenue of $385.8 million and provided guidance for the current quarter and full fiscal year 2026.
Medifast shifts to metabolic health, projects 2026 annual loss
Medifast announced its Q4 and full-year 2025 financial results, reporting revenue of $75.1 million and a net loss of $18.1 million for Q4 2025, and a full-year net loss of $18.7 million. The company is shifting its focus to metabolic health, aiming for profitability, and anticipates full-year 2026 revenue between $270 million and $300 million with a projected loss per share ranging from $1.55 to $2.75. This strategic pivot comes amid challenges like the rapid adoption of GLP-1 medications, which have impacted its active earning coaches and client acquisition.
What to Expect from Medifast's Earnings
Medifast (NYSE: MED) is set to announce its quarterly earnings on February 17, 2026, with analysts estimating an EPS of $-0.80. The company's stock has seen a 33.23% decline over the last 52 weeks, potentially causing concern for long-term shareholders. Investors will be closely watching not only whether Medifast beats the EPS estimate but also its guidance for the next quarter, which often influences stock price more significantly than past performance.
Earnings To Watch: Medifast (MED) Reports Q4 Results Tomorrow
Medifast (NYSE:MED) is set to report its Q4 results soon, with analysts expecting a 40% year-on-year revenue decline to $71.4 million and an adjusted loss of -$0.82 per share. Despite positive sentiment in the personal care segment, Medifast's stock is down 7.6% over the last month, heading into earnings with an average analyst price target of $15. The company met revenue expectations last quarter but has missed Wall Street's revenue estimates three times in the last two years.
Precision Trading with Medifast Inc (MED) Risk Zones
This article analyzes Medifast Inc (MED) using AI models to provide precise trading strategies. It highlights weak sentiment across all time horizons, suggesting a short bias, and details specific entry zones, targets, and stop losses for long, breakout, and short positions. The analysis points to an exceptional 42.0:1 risk-reward setup, targeting a 12.2% gain against 0.3% risk.
Medifast's Q4 Earnings on Deck: What Could Shape MED's Results?
Medifast (MED) is expected to report a significant decline in Q4 fiscal 2025 revenues and a loss per share, attributed to a shrinking active earning OPTAVIA coach base and increased competition from GLP-1 weight loss medications. The company is, however, transitioning towards a broader metabolic health positioning and maintains a strong balance sheet, which may offer some support. Despite these efforts, Medifast's earnings forecast does not conclusively predict an earnings beat.
Medifast (MED) to Release Earnings on Tuesday
Medifast (NYSE: MED) is scheduled to release its Q4 2025 earnings after market close on Tuesday, February 17, 2026. Analysts predict earnings per share of ($0.80) and revenue of $71.4 million. The stock is currently trading near its 50-day moving average with a high P/E ratio, and institutional investors own a significant portion of its shares.
Analysts Estimate Medifast (MED) to Report a Decline in Earnings: What to Look Out for
Medifast (MED) is projected to report a significant year-over-year decline in earnings and revenue for the quarter ending December 2025, with analysts expecting a quarterly loss of $0.76 per share. Despite a 40% upward revision in the consensus EPS estimate over the last 30 days, Medifast's Earnings ESP of 0% combined with a Zacks Rank of #2 makes it difficult to definitively predict an earnings beat. The article also touches upon US Foods (USFD) which is expected to report positive earnings growth for the same period.
Medifast Inc Is Back In The Chat: Viral Glow-Up Or Total Flop?
Medifast Inc is undergoing a significant transition, facing increased competition from GLP-1 medications and wellness apps while its stock experiences volatility. The article evaluates whether the company's structured meal plans and coaching model can adapt to a market that now demands more flexible, sustainable, and affordable weight-loss solutions. It concludes that Medifast is currently a high-risk, story-dependent play for investors and a cautious choice for consumers, requiring significant commitment.
Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025
Medifast (NYSE: MED) will announce its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, February 17, 2026, after market close. The company will host a conference call at 4:30 p.m. ET to discuss the results, featuring CEO Dan Chard, President Nick Johnson, and CFO Jim Maloney. The call will be accessible via webcast on Medifast's Investor Relations website and through a dial-in number.
How coaching helped one woman beat metabolic dysfunction and lose weight
Medifast (NYSE: MED) is celebrating Tiffany Howard's metabolic health transformation, recently featured in People magazine, through its OPTAVIA program. Howard's journey highlights the effectiveness of OPTAVIA's science-backed nutrition, personalized coaching, and habit-building in reversing metabolic dysfunction and achieving healthy weight loss. Medifast emphasizes that Tiffany's story underscores the widespread challenge of metabolic dysfunction and the urgent need for comprehensive solutions like OPTAVIA.
Spain’s lifestyle secrets to metabolic health star in new OPTAVIA film
Medifast's OPTAVIA has premiered "Health by Design: Spain," the second episode in its docuseries exploring cultural, environmental, and community-driven factors that promote long, healthy lives. The episode focuses on Galicia and Madrid, highlighting Spain's lifestyle as a model for metabolic health and longevity. It emphasizes community, routine, an active lifestyle, and their connection to a longer healthspan, aligning with OPTAVIA's mission to address the metabolic dysfunction crisis.
3 Reasons to Avoid MED and 1 Stock to Buy Instead
The article discusses why investors should avoid Medifast (MED), highlighting a significant 18.9% stock price decline for shareholders alongside a 36% annual revenue decrease and a 90.9% annual EPS decline over the last three years. The authors identify revenue decline, limited distribution channels as a small company, and decreasing EPS as key reasons for Medifast's anticipated underperformance, despite an optically cheap valuation. Instead, it suggests looking into high-quality growth stocks that have historically outperformed the market, providing examples like Nvidia and Comfort Systems.
Medifast Shifts to Metabolic Health: A Durable Growth Path?
Medifast is strategically repositioning itself from a weight-loss company to a leader in the metabolic health market, driven by the high prevalence of metabolically unhealthy adults and the limitations of GLP-1 medications. The company's clinical approach focuses on preserving lean muscle, reducing visceral fat, and improving overall body composition, with plans for new product innovations. Despite a promising long-term growth path, Medifast currently holds a Zacks Rank #4 (Sell) due to recent stock performance and projected earnings declines.
Medifast announces leadership changes and CEO succession transition
Medifast announced significant leadership changes, including the departure of Chief Business Operations Officer Anthony Tyree and the promotion of Nicholas Johnson to President, signaling his role in CEO succession planning. Chairman and CEO Daniel Chard will transition to non-executive Chairman in June 2026. The company faces financial challenges, with TipRanks' AI Analyst giving MED a "Neutral" rating due to declining revenue, profitability, and bearish technical indicators.
Medifast announces leadership changes and CEO succession transition
Medifast (MED) is undergoing significant leadership changes, with Chief Business Operations Officer Anthony Tyree departing and Nicholas Johnson promoted to President, broadening his responsibilities. CEO Daniel Chard will transition to non-executive Chairman in June 2026, formalizing a succession plan. Despite these strategic moves, financial performance and technical analysis indicate challenges for the company.
Medifast announces CEO succession plan, Johnson named president By Investing.com
Medifast (NYSE:MED) has announced a CEO succession plan where Nicholas Johnson will take over from Dan Chard in June 2026. Johnson has been appointed President immediately and is currently the Chief Field Operations Officer. This announcement comes as Medifast's stock is trading near its 52-week low and analysts forecast a loss for fiscal year 2025.
Medifast Announces Planned Leadership Transition
Medifast, Inc. (NYSE: MED) announced a planned leadership transition including Nicholas Johnson's appointment as President, effective immediately. He is expected to succeed Dan Chard as CEO in June 2026, with Chard remaining as Chairman. This transition aims to provide continuity as Medifast evolves into a metabolic health company, while Chief Business Operations Officer Tony Tyree will be leaving the company.
CEO of local public company to step down after nearly 10 years
Medifast CEO Dan Chard will resign in June after almost a decade leading the weight-loss company. He transformed the Baltimore-based firm into a billion-dollar operation, but his successor faces the challenge of reversing years of declining revenue.
Nicholas Johnson
Medifast, Inc., parent company of OPTAVIA, announced a leadership transition plan for its CEO role. Current Chairman and CEO Dan Chard will step down in June 2026, with Chief Field Operations Officer Nicholas Johnson immediately moving into the President role. Johnson will assume the CEO position following Chard's departure, who will remain Chairman of the Board.
Medifast Names Nicholas Johnson President Ahead of CEO Succession
Medifast (NYSE: MED) has announced a leadership transition plan, appointing Nicholas Johnson as President, effective immediately, with the expectation that he will become CEO in June 2026. This follows current Chairman and CEO Dan Chard's decision to step down from the CEO role at that time, though he will remain as Chairman. The company aims to ensure continuity as it focuses on its evolution toward metabolic health, recognizing Johnson's instrumental role in this strategic shift.
Medifast (NYSE: MED) outlines CEO succession, President promotion and severance
Medifast (NYSE: MED) has announced significant leadership changes including a CEO transition, a President promotion, and an executive departure. Daniel Chard, current CEO and Chairman, will transition to non-executive Chairman on June 1, 2026, with a reduced compensation package. Nicholas Johnson has been promoted to President, effective January 5, 2026, consolidating additional responsibilities under his role, while Chief Business Operations Officer Anthony Tyree will depart the company on December 31, 2025, receiving a severance package.
Medifast announces CEO succession plan, Johnson named president
Medifast, Inc. announced a CEO succession plan, appointing Nicholas Johnson as president with plans for him to succeed Dan Chard as CEO in June 2026. This leadership transition occurs while the company's stock, trading near its 52-week low, faces challenges including analysts forecasting a loss for fiscal year 2025. Medifast is repositioning itself as a metabolic health company and recently reported a significant revenue decline and net loss for Q3 2025.
Medifast executive Anthony Tyree to depart as operations chief
Medifast Inc. (NYSE: MED) announced that Anthony Tyree will resign from his role as Chief Business Operations Officer and all other positions at the company, effective December 31, 2025. The company stated that Tyree's departure is not due to any disagreement with management or issues related to operations, policies, or practices. The agreement for his departure was reached on December 30, 2025.
Medifast's Third-Quarter Revenue Fell 36%: Is Stabilization Near?
Medifast (MED) reported a 36.2% year-over-year revenue decline in Q3 2025, primarily due to a significant decrease in active earning OPTAVIA coaches. The company expects stabilization to begin in Q4 2025, with revenue growth following one to two quarters later, driven by restructuring, a renewed focus on coach economics, and digital investments. Despite current challenges, management anticipates growth in revenue per active earning coach within six months.
Can Medifast Overcome GLP-1 Pressure With Its Growth Strategy?
Medifast is addressing the evolving weight-loss market by focusing on metabolic health and "metabolic synchronization" to differentiate itself from GLP-1 drugs. The company's strategy involves supporting clients with or without GLP-1 use, investing in digital platforms, and enhancing coach support to improve long-term wellness and retention. Despite a recent share decline and a "Sell" rating from Zacks, Medifast aims for sustainable growth by emphasizing overall metabolic function rather than just weight loss.
Can Medifast Overcome GLP-1 Pressure With Its Growth Strategy?
Medifast is adapting to the rise of GLP-1 drugs by shifting its focus to "metabolic synchronization" to offer longer-term health solutions beyond appetite suppression. The company's strategy involves digital platform investments, simplified pricing, and coach-led support to improve client retention and outcomes. Despite recent share declines and negative earnings forecasts, Medifast aims to create a differentiated growth path complementing or extending GLP-1 use.
Can Medifast Overcome GLP-1 Pressure With Its Growth Strategy?
Medifast is addressing the evolving weight-loss landscape, significantly impacted by GLP-1 drugs, by positioning itself as a leader in metabolic health through its "metabolic synchronization" strategy. This approach aims to reverse metabolic dysfunction and improve body composition, offering a long-term wellness solution that can complement or extend beyond GLP-1 use. Despite a "Sell" rating from Zacks and recent stock underperformance, Medifast's focus on digital platforms, coach-led support, and differentiated growth strategy aims to capitalize on the opportunity to restore natural metabolic function in individuals.
Medifast (MED) Stock Gains on $16.50 Analyst Target | December 2025 - News and Statistics
Shares of Medifast (NYSE:MED) rose 3.5% after analysts set a consensus price target of $16.50, implying a potential 51.31% upside. Despite this gain, the stock is down 34.9% since the beginning of 2025 and is significantly below its 52-week high, indicating investor caution despite positive analyst sentiment. The article also provides a detailed overview of various market research report sections available from IndexBox.
Why Medifast (MED) Stock Is Up Today
Shares of Medifast (NYSE:MED) jumped 3.6% after a consensus analyst price target suggested a potential upside of over 51%. A survey of recent analyst ratings set a target price of $16.50 for Medifast, implying a 51.31% gain from its trading price at the time of the report. This bullish outlook resonated with investors, although the shares cooled slightly after an initial pop.
Medifast (NYSE:MED) Upgraded at Wall Street Zen
Wall Street Zen upgraded Medifast (NYSE:MED) from a "sell" to a "hold" rating, despite other analysts reaffirming a "sell" rating and a consensus "Reduce" rating with a $16.50 target price. The company missed Q3 EPS expectations, reported ($0.21) versus an estimated ($0.01), but revenue beat estimates, and it has provided Q4 2025 guidance of -1.25 to -0.70 EPS. Medifast shares recently traded near their one-year low of $10.91, with a market capitalization of approximately $120 million.
How Medifast Inc (MED) Affects Rotational Strategy Timing
An analysis of Medifast Inc (NYSE: MED) indicates a near-term neutral sentiment suggesting a pause in mid and long-term weakness. The stock shows an exceptional 54.3:1 risk-reward setup, targeting a 15.8% gain against a 0.3% risk. Three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—have been generated by AI models for different risk profiles.
Medifast's Q3 Loss Wider Than Expected, Sales Decline 36% Y/Y
Medifast (MED) reported a wider-than-expected loss of 21 cents per share in Q3 2025, a significant reversal from the prior year's earnings. Net revenues declined 36.2% year-over-year to $89.4 million, primarily due to a reduction in active earning OPTAVIA coaches and the impact of GLP-1 medications for weight loss. The company is shifting its strategy from weight-loss to metabolic health, aiming for a more sustainable market.
Medifast Announces Third Quarter 2025 Financial Results
Medifast reported third-quarter 2025 financial results, with revenue decreasing 36.2% to $89.4 million and a net loss of $2.3 million. The company is actively transforming from a weight-loss focus to promoting metabolic health, attributing revenue challenges to the growing acceptance of GLP-1 medications. Medifast maintains a strong balance sheet with $173.5 million in cash and no debt, positioning itself for this strategic evolution.
Medifast Inc - Announces Strategic Transformation To Metabolic Health With Introduction Of Metabolic Synchronization
Medifast Inc. (MED) has announced a strategic transformation towards metabolic health with the introduction of "Metabolic Synchronization." The company plans to launch new products using this approach in 2026. This move signals a significant shift in Medifast's business focus.
Medifast Inc $MED Shares Sold by Prescott Group Capital Management L.L.C.
Prescott Group Capital Management L.L.C. significantly reduced its stake in Medifast Inc. by 27.3% during the second quarter, selling 30,031 shares. Despite negative analyst sentiment and an EPS miss, institutional investors still hold 95.51% of Medifast's stock, though several have adjusted their positions. The company is trading near its 12-month low, and analysts predict a "Reduce" consensus rating with an average target price of $16.50.
Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2025
Medifast (NYSE: MED) will announce its financial results for the quarter ended September 30, 2025, on Monday, November 3, 2025, after market close. The company will host a conference call at 4:30 p.m. ET on November 3, 2025, with CEO Dan Chard and CFO Jim Maloney, which will be accessible via webcast and telephone. A telephonic playback will also be available for a week following the event.
